Soft pastels · Free shipping over $75 · Shop the boutique
Login Register
eccogene glp 1

eccogene glp 1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases AstraZeneca's oral GLP-1 scored phase

SKU: 44220545970

4.2
USD27.68 USD67.68

Pay in 4 interest-free payments of $6.92 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

doi: 10.1016/j.cll.2013.11.001

eccogene glp 1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases AstraZeneca's oral GLP-1 scored phase

The peptide achieves 60% reduction in ROS levels in WI-38 cells pretreated with 10 nM-10 M GHK-Cu then exposed to 150 M hydrogen peroxide

eccogene glp 1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases AstraZeneca's oral GLP-1 scored phase

Reduce dark spots and unify skin tone

eccogene glp 1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases AstraZeneca's oral GLP-1 scored phase

Mediterr J Soc Sci 5(19):101107

eccogene glp 1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases AstraZeneca's oral GLP-1 scored phase
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products